Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer

Published:2007-04-17 Issue:8 Volume:99 Page:628-638
ISSN:0027-8874
Container-title:JNCI Journal of the National Cancer Institute
language:en
Short-container-title:JNCI Journal of the National Cancer Institute

Author:

Scaltriti M.,Rojo F.,Ocana A.,Anido J.,Guzman M.,Cortes J.,Di Cosimo S.,Matias-Guiu X.,Ramon y Cajal S.,Arribas J.,Baselga J.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/99/8/628/7689446/djk134.pdf

Reference36 articles.

1. Molecular approach to breast cancer treatment

2. ERBB receptors and cancer: the complexity of targeted inhibitors

3. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

4. Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer

5. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.

Cited by 698 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Non-Canonical p75HER2 Signaling Pathway Underlying Trastuzumab Action and Resistance in Breast Cancer;Cells;2024-08-29

2. History of trastuzumab: a case study in health technology reassessment and natural disinvestment in Veneto Region;Frontiers in Pharmacology;2024-08-06

3. PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer;Cancer Letters;2024-08

4. Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies;MedComm;2024-07-28

5. Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer;Cancers;2024-07-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3